A
Adagio Medical
Developing innovative cryoablation technologies that create continuous, linear, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation
About Adagio Medical
Adagio Medical Holdings, Inc. is a medical device company, founded in 2011 by Olav Bergheim, focused on developing catheter-based cryoablation technologies to treat cardiac arrhythmias. Bergheim, a serial entrepreneur in the life sciences sector, established Adagio as a portfolio company of his accelerator, Fjord Ventures, leveraging his extensive background from Baxter Healthcare and Domain Associates to address unmet needs in cardiac rhythm management. The company operates in the cardiac ablation market, serving electrophysiologists and hospitals that treat patients suffering from conditions like atrial fibrillation, atrial flutter, and ventricular tachycardia. Its business model revolves around the development, clinical validation, and commercialization of its proprietary ablation systems. The company went public in August 2024 through a business combination with a special purpose acquisition company (SPAC), ARYA Sciences Acquisition Corp IV, and is now listed on Nasdaq under the ticker ADGM.
Adagio's core technology is its Ultra-Low Temperature Cryoablation (ULTC) system, which uses near-critical nitrogen at -196°C to create deep, continuous, and durable lesions in heart tissue to interrupt abnormal electrical signals. This differs from conventional cryoablation systems which use a warmer refrigerant. The company has developed several products based on this platform. The iCLAS™ system received CE Mark approval in Europe in June 2020 for treating paroxysmal and persistent atrial fibrillation. The vCLAS™ Cryoablation System, specifically designed for treating monomorphic ventricular tachycardia (VT), also secured CE Mark approval and began a limited commercial launch in Europe. A key milestone was achieved in April 2025 when the FDA granted the vCLAS™ system Breakthrough Device Designation for treating drug-refractory VT, a status intended to expedite its review and potential access for U.S. patients. The company is currently focused on its FULCRUM-VT pivotal IDE study in the U.S. and Canada to support FDA premarket approval for the vCLAS system.
The company's strategy involves securing regulatory approvals and demonstrating clinical efficacy to drive adoption. After going public, Adagio has undergone a strategic restructuring to prioritize the U.S. pivotal trial for its vCLAS catheter, pausing the European launch to focus resources. In late 2024, a leadership transition occurred, with Todd Usen, a veteran of the medical device industry, appointed as CEO to guide the company through its next phase of clinical and commercial development. Adagio has raised significant capital through various funding rounds, including a $42.5 million Series E in 2020 and approximately $84.2 million from its SPAC merger, with backing from investors like RA Capital Management, Perceptive Advisors, and ArrowMark Partners.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VCOther financing | Dec 2025 | $50M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT NON VCOther financing | Oct 2025 | $19M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Adagio Medical is 1.7K monthly website visits, up 6.3% over the last three months. Adagio Medical's team grew 14.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Adagio Medical in the Laguna Hills ecosystem
The Adagio Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
JMR Capital
Fjord Ventures
ArrowMark Partners
Perceptive Advisors
RA Capital Management- AIARYA Sciences Acquisition Corp IV
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adagio Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adagio Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









